# Chimera Clinical Advisory Board Charter (Enhanced Version)

<div align="center">
<img src="https://img.shields.io/badge/-%F0%9F%A7%A0%20CHIMERA%20CLINICAL%20ADVISORY%20BOARD%20%F0%9F%A6%BE-6236FF?style=for-the-badge&labelColor=1A1A2E" alt="Chimera Clinical Advisory Board"/>

**Guiding the Future of Brain-Controlled Exoskeleton Technology**

*Version 2.0 | Effective Date: April 2025*

[![FDA Compliance](https://img.shields.io/badge/FDA-Compliance%20Ready-green?style=flat-square&logo=data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAyNCAyNCI+PHBhdGggZD0iTTEyIDJDNi41IDIgMiA2LjUgMiAxMnM0LjUgMTAgMTAgMTAgMTAtNC41IDEwLTEwUzE3LjUgMiAxMiAyem0tMSAxNkg3di0yaDR2MnptNi40LTRINi42Yy0uOSAwLTEuNi0uNy0xLjYtMS42VjYuNkM1IDUuNyA1LjcgNSA2LjYgNWgxMC44Yy45IDAgMS42LjcgMS42IDEuNnY1LjhjMCAuOS0uNyAxLjYtMS42IDEuNnoiIGZpbGw9IndoaXRlIi8+PC9zdmc+)](https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd)
[![ISO 14155](https://img.shields.io/badge/ISO%2014155-Clinical%20Investigation-blue?style=flat-square)](https://www.iso.org/standard/71690.html)
[![21 CFR Part 11](https://img.shields.io/badge/21%20CFR%20Part%2011-Compliant-blue?style=flat-square)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11)
</div>

## 1. Executive Summary

The Chimera Clinical Advisory Board (CAB) is a cornerstone of our regulatory and clinical strategy, providing expert guidance for the development, validation, and market introduction of the Chimera brain-computer interface (BCI) controlled exoskeleton platform. This charter establishes a world-class advisory body comprising leading experts in neurology, rehabilitation medicine, neuroscience, bioethics, patient advocacy, regulatory affairs, and clinical research methodology.

The CAB will play a critical role in ensuring that the Chimera platform meets the highest standards of clinical efficacy, safety, and ethical implementation while navigating the complex regulatory landscape for novel neurotechnology devices. Through strategic guidance on clinical trial design, regulatory pathways, safety monitoring, and technology assessment, the CAB will accelerate our path to market while maximizing clinical impact and commercial success.

This charter defines the CAB's purpose, responsibilities, membership requirements, operational procedures, and governance structure, establishing a framework for leveraging expert insights to achieve our billion-dollar market potential.

## 2. Purpose and Scope

### 2.1 Mission Statement

The Chimera Clinical Advisory Board exists to ensure that our brain-controlled exoskeleton technology achieves optimal clinical outcomes, maintains the highest safety standards, and navigates regulatory pathways efficiently while addressing ethical considerations in neurotechnology implementation.

### 2.2 Strategic Objectives

The CAB will support Chimera in achieving the following strategic objectives:

1. **Accelerate Regulatory Approval**: Provide expert guidance to optimize regulatory strategy and expedite FDA clearance/approval
2. **Enhance Clinical Validation**: Design and oversee robust clinical studies that demonstrate safety and effectiveness
3. **Maximize Therapeutic Impact**: Identify optimal patient populations and clinical protocols to maximize therapeutic benefits
4. **Ensure Ethical Implementation**: Address neuroethical considerations and establish responsible use guidelines
5. **Support Market Adoption**: Develop strategies for clinical integration and reimbursement pathways
6. **Maintain Competitive Advantage**: Provide insights on emerging technologies and competitive positioning

### 2.3 Scope of Authority

The CAB serves in an advisory capacity to Chimera leadership with the following scope:

- Provides recommendations on clinical and regulatory strategy
- Reviews and advises on clinical study designs and protocols
- Evaluates safety data and recommends risk mitigation strategies
- Offers guidance on ethical considerations and responsible implementation
- Does not have direct decision-making authority over company operations
- Cannot commit company resources without executive approval

## 3. Responsibilities

### 3.1 Clinical Strategy Development

#### 3.1.1 Clinical Trial Design and Oversight
- Develop comprehensive clinical development plan aligned with regulatory requirements
- Design statistically rigorous clinical trial protocols with appropriate endpoints
- Recommend inclusion/exclusion criteria to optimize patient selection
- Advise on site selection and investigator qualifications
- Review clinical study progress and interim results
- Recommend protocol modifications based on emerging data

#### 3.1.2 Outcome Measures and Endpoints
- Identify clinically meaningful primary and secondary endpoints
- Recommend validated assessment tools and measurement techniques
- Advise on patient-reported outcome measures
- Develop strategies for long-term efficacy monitoring
- Guide development of novel outcome measures specific to BCI-controlled exoskeletons

#### 3.1.3 Therapeutic Protocol Development
- Design optimal protocols for device calibration and patient training
- Establish guidelines for therapy progression and intensity
- Develop protocols for home use vs. clinical setting use
- Create standards for therapist training and certification
- Recommend approaches for personalizing therapy to individual patients

### 3.2 Regulatory Guidance

#### 3.2.1 Regulatory Strategy
- Advise on optimal regulatory pathways (510(k), De Novo, PMA)
- Guide preparation for pre-submission meetings with FDA
- Review regulatory submissions for clinical content accuracy
- Provide insights on international regulatory approaches (EU MDR, PMDA, etc.)
- Advise on post-market surveillance requirements

#### 3.2.2 Documentation Review
- Review clinical sections of regulatory submissions
- Evaluate clinical evidence summaries and clinical evaluation reports
- Assess benefit-risk analyses for regulatory purposes
- Review clinical validation protocols and reports
- Provide expert opinions for regulatory responses

#### 3.2.3 Compliance Oversight
- Ensure clinical studies comply with GCP requirements
- Advise on implementation of 21 CFR Part 11 for clinical data
- Guide compliance with human subject protection regulations
- Provide insights on evolving regulatory requirements for AI/ML in medical devices
- Advise on clinical aspects of quality system implementation

### 3.3 Safety and Ethics Oversight

#### 3.3.1 Safety Monitoring
- Establish safety monitoring protocols for clinical studies
- Review adverse event reports and recommend responses
- Develop risk mitigation strategies for identified safety concerns
- Advise on post-market surveillance methodologies
- Guide development of safety training materials for users

#### 3.3.2 Ethical Framework Development
- Establish ethical guidelines for BCI technology implementation
- Address privacy concerns related to neural data collection
- Develop protocols for informed consent in vulnerable populations
- Provide guidance on equitable access considerations
- Address potential psychological impacts of BCI technology

#### 3.3.3 Risk Management
- Review risk analysis documentation
- Advise on risk control implementation
- Evaluate residual risk acceptability
- Guide benefit-risk determinations
- Recommend approaches for communicating risks to users

### 3.4 Technology Assessment

#### 3.4.1 Clinical Utility Evaluation
- Assess technology performance in clinical settings
- Evaluate user experience from patient and clinician perspectives
- Identify opportunities for technology refinement
- Compare performance to standard of care and competitive technologies
- Recommend feature prioritization based on clinical impact

#### 3.4.2 Technical Performance Review
- Evaluate BCI signal acquisition and processing performance
- Assess exoskeleton mechanical performance and safety
- Review human factors and usability testing results
- Provide feedback on user interface design
- Evaluate algorithm performance and adaptation capabilities

#### 3.4.3 Innovation Guidance
- Identify unmet clinical needs for future development
- Recommend technology enhancements based on clinical experience
- Advise on integration with complementary technologies
- Guide development of next-generation features
- Provide insights on emerging competitive technologies

### 3.5 Knowledge Dissemination

#### 3.5.1 Publication Strategy
- Guide development of publication plan for clinical results
- Review key manuscripts prior to submission
- Recommend target journals and conferences
- Advise on addressing reviewer comments
- Support development of white papers and review articles

#### 3.5.2 Clinical Education
- Guide development of training materials for clinicians
- Advise on certification programs for clinical users
- Support creation of patient education materials
- Recommend approaches for clinical community engagement
- Provide guidance on medical education initiatives

#### 3.5.3 Stakeholder Engagement
- Facilitate connections with key opinion leaders
- Support engagement with patient advocacy organizations
- Advise on payer and health system education
- Guide development of value proposition messaging
- Support engagement with professional societies

## 4. Membership Composition

### 4.1 Expertise Requirements

The CAB consists of 7-9 members representing diverse expertise relevant to brain-controlled exoskeletons:

<table>
<tr>
<th>Expertise Area</th>
<th>Required Experience</th>
<th>Key Responsibilities</th>
<th>Number of Members</th>
</tr>
<tr>
<td><strong>Neurology</strong></td>
<td>
• Expertise in motor neuron diseases, spinal cord injury, or stroke rehabilitation<br>
• Experience with brain-computer interfaces in clinical settings<br>
• Board certification in neurology<br>
• Minimum 10 years clinical practice<br>
• Publication record in relevant areas
</td>
<td>
• Lead clinical protocol development<br>
• Evaluate neurological safety aspects<br>
• Guide patient selection criteria<br>
• Advise on neurological outcome measures<br>
• Support regulatory neurological assessments
</td>
<td align="center">1-2</td>
</tr>
<tr>
<td><strong>Physical Medicine and Rehabilitation</strong></td>
<td>
• Expertise in exoskeleton-assisted rehabilitation<br>
• Experience with mobility assistive technologies<br>
• Board certification in PM&R<br>
• Minimum 8 years clinical practice<br>
• Experience in rehabilitation technology implementation
</td>
<td>
• Guide rehabilitation protocol development<br>
• Advise on functional outcome measures<br>
• Evaluate usability in rehabilitation settings<br>
• Develop therapist training requirements<br>
• Support reimbursement strategy
</td>
<td align="center">1-2</td>
</tr>
<tr>
<td><strong>Neuroscience/Neurophysiology</strong></td>
<td>
• Expertise in EEG signal processing and interpretation<br>
• Understanding of motor control and neural plasticity<br>
• PhD in neuroscience or related field<br>
• Research experience with BCI technology<br>
• Publication record in neural signal processing
</td>
<td>
• Evaluate BCI algorithm performance<br>
• Guide signal processing improvements<br>
• Advise on neuroplasticity considerations<br>
• Support technical performance assessment<br>
• Guide development of novel BCI approaches
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Bioethics</strong></td>
<td>
• Expertise in neuroethics and emerging technologies<br>
• Experience with regulatory ethics committees<br>
• Formal training in bioethics<br>
• Publication record in neuroethics<br>
• Experience with IRB or ethics committees
</td>
<td>
• Develop ethical framework for technology use<br>
• Guide informed consent processes<br>
• Advise on privacy protections for neural data<br>
• Address equity and access considerations<br>
• Support responsible innovation practices
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Patient Advocacy</strong></td>
<td>
• Representative from relevant patient community<br>
• Experience in patient-centered research design<br>
• Connection to patient advocacy organizations<br>
• Understanding of lived experience with mobility impairment<br>
• Experience in patient advisory roles
</td>
<td>
• Ensure patient perspective in development<br>
• Guide development of patient-reported outcomes<br>
• Advise on user experience considerations<br>
• Support patient recruitment strategies<br>
• Facilitate connections with patient communities
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Regulatory Affairs</strong></td>
<td>
• Experience with FDA medical device approval processes<br>
• Knowledge of Software as a Medical Device (SaMD) regulations<br>
• RAC certification preferred<br>
• Minimum 8 years in regulatory affairs<br>
• Experience with Class II/III medical device submissions
</td>
<td>
• Guide regulatory strategy development<br>
• Advise on regulatory submission content<br>
• Support preparation for FDA meetings<br>
• Provide insights on international regulations<br>
• Advise on post-market requirements
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Clinical Research Methodology</strong></td>
<td>
• Expertise in clinical trial design and biostatistics<br>
• Experience with medical device clinical studies<br>
• PhD in biostatistics, epidemiology, or related field<br>
• Publication record in clinical research methods<br>
• Experience with adaptive trial designs
</td>
<td>
• Design statistically rigorous clinical trials<br>
• Develop data analysis plans<br>
• Advise on sample size and power calculations<br>
• Guide interim analysis approaches<br>
• Support clinical evidence synthesis
</td>
<td align="center">1</td>
</tr>
</table>

### 4.2 Member Selection Criteria

Members will be selected based on the following criteria:

1. **Professional Qualifications**: Demonstrated expertise in relevant field with appropriate credentials
2. **Industry Recognition**: Standing as a key opinion leader or recognized expert
3. **Research Contributions**: Publication record and research impact in relevant areas
4. **Clinical Experience**: Direct experience with relevant patient populations or technologies
5. **Regulatory Knowledge**: Understanding of regulatory requirements for medical devices
6. **Collaborative Approach**: Demonstrated ability to work effectively in advisory roles
7. **Diversity Considerations**: Representation across gender, geography, and professional backgrounds
8. **Conflict Management**: Ability to manage potential conflicts of interest appropriately

### 4.3 Diversity and Inclusion

The CAB will prioritize diversity across multiple dimensions:

- **Gender Balance**: Minimum 40% representation of any gender
- **Geographic Diversity**: Representation from multiple regions to support global strategy
- **Institutional Diversity**: Members from academic, clinical, industry, and advocacy settings
- **Perspective Diversity**: Inclusion of varied viewpoints and approaches
- **Career Stage Diversity**: Mix of established leaders and emerging experts

## 5. Appointment and Terms

### 5.1 Selection Process

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1kk9PwzAMxb9KlBOI9QvkMG3qBBJiB8QOvUQmMY3WJlWSMjZV_e7YbVlhwJf4-fez_OzCuJUEBbwQb8lYvGvDLZIVUXxA8t5ZJA_WkVYRXdA6JGQvVkWUhLxGRWQMqQhXZJV3pCNcxHmcx1mcx_9i5_uoI1zGeZzHeZzH-b_YRYRXcR7ncR7ncR7nMXZ-jjrCdZzHeZzHeZzHeYyd36KO8C7O4zzO4zzO4zzGzh9RR_gY53Ee53Ee53EeY-fPqCP8ivM4j_M4j_M4j7HzLuoIf-I8zuM8zuM8zmPs_Bt1hMc4j_M4j_M4j_MYO0-ijvAU53Ee53Ee53EeY-c0wlOcx3mcx3mcx3mMnbMIT3Ee53Ee53Ee5zF2ziM8xXmcx3mcx3mcx9i5iPAU53Ee53Ee53EeY-cywnOcx3mcx3mcx3mMnasIz3Ee53Ee53Ee5zF2riO8xHmcx3mcx3mcx9i5ifAS53Ee53Ee53EeY-c2wkucx3mcx3mcx3mMnbsIL3Ee53Ee53Ee5zF27iO8xnmcx3mcx3mcx9h5iPAa53Ee53Ee53EeY-cxwmucx3mcx3mcx3mMnacIb3Ee53Ee53Ee5zF2niO8xXmcx3mcx3mcx9h5ifAW53Ee53Ee53EeY-c1wlucx3mcx3mcx3mMnbcI73Ee53Ee53Ee5zF23iO8x3mcx3mcx3mcx9j5iPAe53Ee53Ee53EeY-czwnucx3mcx3mcx3mMna8IH3Ee53Ee53Ee5zF2viN8xHmc
(Content truncated due to size limit. Use line ranges to read in chunks)